pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$PIIPolaris Inc.

$PII68.33-1.67%
Medina, MN, USupdated 4h ago

Polaris is a yellow supergiant star in the northern circumpolar constellation of Ursa Minor. It is designated α Ursae Minoris and is commonly called the North Star. With an apparent magnitude that fluctuates around 1.98, it is the brightest star in the constellation and is readily visible to the naked eye at night. The position of the star lies less than 1° away from the north celestial pole, making it the current northern pole star. The stable position of the star in the Northern Sky makes it useful for navigation.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
pre_registration: 1
1pre_registration
pre_registration
pegargiminase
Malignant Pleural Mesothelioma

📅 Upcoming

Oct 26, 2026
earnings
$PII68.33-1.67%
in 2mo
Polaris Inc. earnings
Polaris Inc.
→

🕒 Recent(90d)

earnings (1)
Jul 27, 2026
earnings
$PII68.33-1.67%
22d ago
Polaris Inc. earnings
Polaris Inc.
→
view all catalysts →

Active trials

  • phase3Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)recruitingn=300
  • phase1Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemiaactive not recruitingn=38
  • phase3Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinomarecruitingn=300
  • phase2Study of ADI-PEG 20 Versus Placebo in Subjects With NASHrecruitingn=60
  • phase2ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiformeactive not recruitingn=100
  • phase3Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatincompletedn=249

Insider activity

source: SEC Form 4
routine RSU / option mechanics (6)
  • Apr 1, 26grantHendrickson Gary E · director651 sh
  • Apr 1, 26grantBilicic George W · director640 sh
  • Apr 1, 26grantKESSLER BERND F · director606 sh
  • Apr 1, 26grantHenricks Gwenne A. · director560 sh
  • Apr 1, 26grantShotwell Gwynne · director560 sh
  • Mar 2, 26option exerciseMack Robert Paul · CFO, EVP - Finance + Corp Dev23 sh
🐶 Hiring Signal
next earnings Oct 26, 2026
No open roles indexed yet — view Polaris Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$PII
SEC CIK
0000931015
country
US
source
sec_tickers
top tags
Oncology1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 28m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?